Active peptide for senescent cells and preparation method thereof
By designing polypeptide active peptides that bind to the gp130 receptor, the problem of insufficient targeting of existing anti-aging drugs has been solved, enabling specific intervention and tissue repair of senescent cells, and exhibiting long-term delivery and self-assembly properties.
Patent Information
- Application Number
- CN202610436805.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-04-03
- Publication Date
- 2026-05-01
- Estimated Expiration
- 2046-04-03
AI Technical Summary
Existing anti-aging interventions, such as small molecule drugs, lack sufficient targeting and have systemic side effects. Antibody drugs are costly to prepare and have limited tissue penetration. Peptide molecules have advantages in terms of structural designability and tissue penetration, but further optimization is needed to achieve SASP that specifically antagonizes aging cells.
An active peptide was designed by mimicking the helical structure of the IL-6R protein, binding to the Site II region of the gp130 receptor, optimizing the amino acid sequence to H2N-FFGFLGRYFQKWEKLRNQ, and introducing the FF-GFLG module to achieve self-assembly and enzyme cleavage recognition. The preparation method includes peptide synthesis, cleavage, and precipitation steps.
It achieves specific intervention on senescent cells, blocks IL-6R signal transduction, inhibits the secretion of pro-inflammatory factors, delays cell senescence, promotes tissue repair, and achieves long-term delivery and local release through self-assembled nanostructures.